当前位置: 首页 > 期刊 > 《中国当代医药》 > 2019年第14期
编号:13378503
ANO1蛋白在胃腺癌组织中表达及临床意义(4)
http://www.100md.com 2019年5月15日 《中国当代医药》 2019年第14期
     [16]Guan L,Song Y,Gao J,et al.Inhibition of calcium-activated chloride channel ANO1 suppresses proliferation and induces apoptosis of epithelium originated cancer cells[J].Oncotarget,2016,7(48):78 619-78 630.

    [17]Gomez-Martin C,Plaza JC,Pazo-Cid R,et al.Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab[J].J Clin Oncol,2013,31(35):4445-4452.

    [18]Sanford M.Trastuzumab:a review of its use in HER2-positive advanced gastric cancer[J].Drugs,2013,73(14):1605-1615.

    [19]Kulkarni S,Bill A,Godse NR,et al.TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2[J].Genes Chromosomes Cancer,2017,56(6):460-471.

    [20]Fujimoto M,Inoue T,Kito H,et al.Transcriptional repression of HER2 by ANO1 Cl- channel inhibition in human breast cancer cells with resistance to trastuzumab[J].Biochem Biophys Res Commun,2017,482(1):188-194.

    (收稿日期:2018-12-04 本文編辑:任秀兰), http://www.100md.com(白璐 王涛 张喆)
上一页1 2 3 4